ClinicalTrials.gg

Anemia clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,810 studies for Anemia across more than 10 countries. 215 are recruiting or about to start. 1,106 of them are mainly about Anemia (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its 22 narrower conditions too, such as Anemia, Sickle Cell: 4,772 studies, 830 open.

ClinicalTrials.gov finds 5,304 studies for Anemia. How that becomes 1,810 here

This page counts the studies the registry files under Anemia, and those it files under no condition that list Anemiathemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 16, 2026. How condition pages count

  1. 5,304Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −2,892Filed under a narrower condition, counted on its own pageAnemia, Sickle Cell 1,081 · Anemia, Iron-Deficiency 445 · Anemia, Aplastic 331 · beta-Thalassemia 196 · Hemoglobinuria, Paroxysmal 154 · Thalassemia 105 · 16 more
  3. −157List Anemia as a condition, but the registry did not file them under itMost often written as “Iron Deficiency (Without Anemia)” (16), “Renal Anemia” (8), and “Anemia of Chronic Kidney Disease” (6). The registry filed them under other conditions only, most often Iron Deficiencies (25) and Anemia, Neonatal (11).
  4. −445Match it another way175 name it in the title, 92 in a keyword, and 178 by a synonym or other text the search reads.
  5. 1,810The count on this page140 of them list Anemia in their own words; the registry filed them under no condition.

Status

Completed
1,157
Status unknown
163
Terminated
154
Recruiting
122
Not yet recruiting
82
Withdrawn
58

Phase

Phase 3
398
Phase 2
334
Phase 4
215
Phase 1
139
Early Phase 1
10

Where

United States
464
Germany
151
France
148
United Kingdom
126
Italy
119
China
115

Who develops what

Add Anemia to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 20 programs from 17 companies, 11 with this as their studies’ main aim; 6 with a live phase 3 study; 5 primary completions in the next 12 months. Compare 3SBio, Shenzhen Salubris Pharmaceuticals and Biocad here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
Epoetin AlfaRecent, repeated
Evidence
  • NCT07422480 · Takeda · Phase 3 · live · comparator · “Epoetin Alfa” · registered Feb 2026
  • NCT05949684 · Bristol-Myers Squibb · Phase 3 · live · comparator · “Epoetin Alfa” · registered Jul 2023
  • NCT03799627 · Akebia Therapeutics · Phase 2 · comparator · “Epoetin Alfa” · registered Dec 2018
  • NCT03682536 · Bristol-Myers Squibb · Phase 3 · live · comparator · “Epoetin alfa” · registered Sep 2018
  • NCT03408639 · Cinnagen · Phase 3 · comparator · “Eprex®” · registered Dec 2017
Johnson & Johnson55% of its industry studiesUS: Amgen (FDA 1989) + 1 otherEU: Hoffmann-La Roche (EMA 1997) + 6 others22 studies
Darbepoetin alfaRecent, repeated
Evidence
  • NCT07300111 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Darbepoetin alfa” · registered Dec 2025
  • NCT06466785 · Genexine, Inc. · Phase 3 · live · comparator · “Darbepoetin Alfa” · registered Jun 2024
  • NCT04313153 · Akebia Therapeutics · Phase 3 · comparator · “Darbepoetin alfa” · registered Mar 2020
  • NCT04027517 · JW Pharmaceutical · Phase 3 · comparator · “Darbepoetin Alfa” · registered Jul 2019
  • NCT03543657 · Bayer · Phase 3 · comparator · “Darbepoetin alfa” · registered May 2018
Amgen81% of its industry studiesUS: Amgen (FDA 2001)EU: Amgen (EMA 2001)22 studies

9 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
AND017☆ Track2 live phase-3 studies: NCT07494409, NCT07487727Kind Pharmaceuticals LLC
daprodustat☆ Track1 live phase-3 study: NCT07300111Qilu Pharmaceutical Co., Ltd.
roxadustatApproved: EU 2021☆ Track1 live phase-3 study: NCT07722988Kyntra Bio
pegdarbepoetin beta☆ Track1 live phase-3 study: NCT07119372Biocad

The 4 in phase 3 with the nearest primary completion, of 20 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (5)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 1 Dec 2026 est.AND017 · Kind Pharmaceuticals LLC · Phase 3 main aim+ AND017 vs HematinicsNCT07487727 A Study of AND017 to Evaluate Efficacy and Safety in Patients With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) — primary endpoint: Evaluate the efficacy of AND017 compared with the active control in maintaining Hemoglobin (Hb) levels in patients with anemia due to CKD · 240 enrolled
  • May 2027 est.daprodustat · Qilu Pharmaceutical Co., Ltd. · Phase 3 main aimvs Darbepoetin alfaNCT07300111 A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD) — primary endpoint: Mean Hemoglobin (Hgb) During the Efficacy Evaluation Period · 100 enrolled
  • May 2027 est.selcodebart · Disc Medicine, Inc · Phase 2 named, not the main aimNCT05320198 Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia — primary endpoint: Safety and Tolerability of DISC-0974 (Phase 1b only) · 150 enrolled

2 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Anemia studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Antimetabolites 1 open · Tyrosine kinase inhibitors (TKIs) 1 open · Alkylating agents 1 open · JAK inhibitors 1 open · NSAIDs 1 open

Coming up

77studies finish main data collection within a year15 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger. 34 (28%) take children under 18. 12 (10%) are for women only and 1 (1%) for men only; 23 (19%) take healthy volunteers.

Recruiting studies that take each age, of 122
AgeWomenMen
1019 (16%)19 (16%)
18106 (87%)94 (77%)
30102 (84%)90 (74%)
40100 (82%)89 (73%)
5098 (80%)89 (73%)
6592 (75%)86 (70%)
7588 (72%)82 (67%)
8580 (66%)74 (61%)

Across all 1,810 studies, recruiting or not: 35% stop at 75 or younger and 29% at 65; 26% take children; 13% are for women only and 2% for men only; 21% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Anemia studies take

Of 149 phase 3 interventional studies under Anemia, half reached primary completion within 30 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 112 mo3–43 · 48 studies6 mo3–30 · 34 studies—
Phase 228 mo16–56 · 88 studies23 mo13–40 · 58 studies—
Phase 330 mo17–51 · 149 studies25 mo15–49 · 98 studies36 mo21–59 · 51 studies
Phase 427 mo17–48 · 73 studies—25 mo17–48 · 59 studies
Interventional, no phase17 mo7–29 · 178 studies—18 mo8–30 · 164 studies
Observational30 mo12–76 · 145 studies—30 mo11–83 · 124 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 1,810. Browse all 1,810 → or search them.